Literature DB >> 15767422

Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

Péter Bagossi1, Tamás Sperka, Anita Fehér, János Kádas, Gábor Zahuczky, Gabriella Miklóssy, Péter Boross, József Tözsér.   

Abstract

The specificities of the proteases of 11 retroviruses representing each of the seven genera of the family Retroviridae were studied using a series of oligopeptides with amino acid substitutions in the P2 position of a naturally occurring type 1 cleavage site (Val-Ser-Gln-Asn-Tyr Pro-Ile-Val-Gln; the arrow indicates the site of cleavage) in human immunodeficiency virus type 1 (HIV-1). This position was previously found to be one of the most critical in determining the substrate specificity differences of retroviral proteases. Specificities at this position were compared for HIV-1, HIV-2, equine infectious anemia virus, avian myeloblastosis virus, Mason-Pfizer monkey virus, mouse mammary tumor virus, Moloney murine leukemia virus, human T-cell leukemia virus type 1, bovine leukemia virus, human foamy virus, and walleye dermal sarcoma virus proteases. Three types of P2 preferences were observed: a subgroup of proteases preferred small hydrophobic side chains (Ala and Cys), and another subgroup preferred large hydrophobic residues (Ile and Leu), while the protease of HIV-1 preferred an Asn residue. The specificity distinctions among the proteases correlated well with the phylogenetic tree of retroviruses prepared solely based on the protease sequences. Molecular models for all of the proteases studied were built, and they were used to interpret the results. While size complementarities appear to be the main specificity-determining features of the S2 subsite of retroviral proteases, electrostatic contributions may play a role only in the case of HIV proteases. In most cases the P2 residues of naturally occurring type 1 cleavage site sequences of the studied proteases agreed well with the observed P2 preferences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767422      PMCID: PMC1061542          DOI: 10.1128/JVI.79.7.4213-4218.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Expression and characterization of human foamy virus proteinase.

Authors:  G Fenyöfalvi; P Bagossi; T D Copeland; S Oroszlan; P Boross; J Tözsér
Journal:  FEBS Lett       Date:  1999-12-03       Impact factor: 4.124

2.  Rational approach to AIDS drug design through structural biology.

Authors:  Alexander Wlodawer
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes.

Authors:  Moses Prabu-Jeyabalan; Ellen Nalivaika; Celia A Schiffer
Journal:  Structure       Date:  2002-03       Impact factor: 5.006

Review 4.  HIV-1 protease: maturation, enzyme specificity, and drug resistance.

Authors:  J M Louis; I T Weber; J Tözsér; G M Clore; A M Gronenborn
Journal:  Adv Pharmacol       Date:  2000

5.  Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase.

Authors:  J M Louis; S Oroszlan; J Tözsér
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

6.  Effect of substrate residues on the P2' preference of retroviral proteinases.

Authors:  P Boross; P Bagossi; T D Copeland; S Oroszlan; J M Louis; J Tözsér
Journal:  Eur J Biochem       Date:  1999-09

Review 7.  Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.

Authors:  R Swanstrom; J Erona
Journal:  Pharmacol Ther       Date:  2000-05       Impact factor: 12.310

8.  Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase.

Authors:  G Zahuczky; P Boross; P Bagossi; G Emri; T D Copeland; S Oroszlan; J M Louis; J Tözsér
Journal:  Biochim Biophys Acta       Date:  2000-03-16

9.  Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.

Authors:  J Tözsér; G Zahuczky; P Bagossi; J M Louis; T D Copeland; S Oroszlan; R W Harrison; I T Weber
Journal:  Eur J Biochem       Date:  2000-10

10.  Characterization of the protease of a fish retrovirus, walleye dermal sarcoma virus.

Authors:  Sharon K Fodor; Volker M Vogt
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

View more
  22 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin.

Authors:  Krisztina Matúz; János Mótyán; Mi Li; Alexander Wlodawer; József Tőzsér
Journal:  FEBS J       Date:  2012-08-17       Impact factor: 5.542

3.  HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Authors:  Marc Potempa; Sook-Kyung Lee; Nese Kurt Yilmaz; Ellen A Nalivaika; Amy Rogers; Ean Spielvogel; Charles W Carter; Celia A Schiffer; Ronald Swanstrom
Journal:  J Mol Biol       Date:  2018-11-07       Impact factor: 5.469

4.  Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.

Authors:  Liwen You; Daniel Garwicz; Thorsteinn Rögnvaldsson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

Authors:  Yunfeng Tie; Yuan-Fang Wang; Peter I Boross; Ting-Yi Chiu; Arun K Ghosh; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  Protein Sci       Date:  2012-01-24       Impact factor: 6.725

6.  Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.

Authors:  Mi Li; Gary S Laco; Mariusz Jaskolski; Jan Rozycki; Jerry Alexandratos; Alexander Wlodawer; Alla Gustchina
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

7.  Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.

Authors:  Sidhartha Chaudhury; Jeffrey J Gray
Journal:  Structure       Date:  2009-12-09       Impact factor: 5.006

8.  A switch-on mechanism to activate maize ribosome-inactivating protein for targeting HIV-infected cells.

Authors:  Sue Ka-Yee Law; Rui-Rui Wang; Amanda Nga-Sze Mak; Kam-Bo Wong; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Nucleic Acids Res       Date:  2010-06-17       Impact factor: 16.971

9.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Authors:  Helga Eizert; Pálma Bander; Péter Bagossi; Tamás Sperka; Gabriella Miklóssy; Péter Boross; Irene T Weber; József Tözsér
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

10.  Role of the foamy virus Pol cleavage site in viral replication.

Authors:  Jacqueline Roy; Maxine L Linial
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.